First Manhattan’s ARK Genomic Revolution ETF ARKG Stock Holding History

First Manhattan’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-300	Closed	-$8.63K	–	701
2024 Q1	$8.63K	Hold	300	–	–	﹤0.01%	1123
2023 Q4	$9.84K	Hold	300	–	–	﹤0.01%	1121
2023 Q3	$8.36K	Hold	300	–	–	﹤0.01%	1163
2023 Q2	$10.2K	Hold	300	–	–	﹤0.01%	1138
2023 Q1	$9.02K	Hold	300	–	–	﹤0.01%	1226
2022 Q4	$8.47K	Hold	300	–	–	﹤0.01%	1287
2022 Q3	$9K	Hold	300	–	–	﹤0.01%	1218
2022 Q2	$9K	Buy	+300	New	+$10.5K	﹤0.01%	1235
2022 Q1	–	Sell	-730	Closed	-$44K	–	1580
2021 Q4	$44K	Sell	730 -20	-3%	-$1.38K	﹤0.01%	1012
2021 Q3	$56K	Hold	750	–	–	﹤0.01%	964
2021 Q2	$69K	Buy	750 +100	+15%	+$8.5K	﹤0.01%	912
2021 Q1	$57K	Buy	650 +50	+8%	+$4.96K	﹤0.01%	932
2020 Q4	$55K	Buy	+600	New	+$47.8K	﹤0.01%	885
2020 Q1	–	Sell	-600	Closed	-$20K	–	1364
2019 Q4	$20K	Hold	600	–	–	﹤0.01%	1039
2019 Q3	$17K	Hold	600	–	–	﹤0.01%	1077
2019 Q2	$20K	Hold	600	–	–	﹤0.01%	1074
2019 Q1	$19K	Buy	+600	New	+$17.7K	﹤0.01%	1098

Other funds holding ARKG

MMEA

Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

First Manhattan's ARKG Position: Q2 2024 in Review

First Manhattan sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2024, closing a stake of 300 shares — an estimated $8.63K sold.

First Manhattan first reported a position in ARKG in Q1 2019 and held it in 17 quarters. The position peaked at $69K in Q2 2021. 261 funds tracked by Wall St. Rank hold ARKG as of Q2 2024.

First Manhattan reported no remaining ARK Genomic Revolution ETF position as of Q2 2024 after selling out during the quarter.
First Manhattan sold 300 ARK Genomic Revolution ETF shares in Q2 2024, an estimated $8.63K.
First Manhattan first reported a position in ARK Genomic Revolution ETF in Q1 2019 and held it in 17 quarters.
First Manhattan's ARK Genomic Revolution ETF position peaked at $69K in Q2 2021.
261 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2024.

Based on First Manhattan's 13F filing for Q2 2024, filed 14 Aug 2024.